Loading
Theralase Technologies Inc. Stock: price and insider trades · Canada
CA·Mcap CA$54.3M
Theralase Technologies Inc.: what insiders have been doing
Theralase Technologies Inc. is a listed company. Filings by its managers are published through SEDI. 6 insiders have disclosed 17 filings since 18 October 2025.
Only purchases show up on the open market, 2 purchases in all worth €5,235, filed by 2 insiders. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 2 senior executives. Dumoulin-White, Roger John filed the largest purchase, €4,681, on 27 August 2026, which represents 0.014% of the company's market value.
With 17 filings in twelve months, the company is more active than the median of 12 filings across the 2,120 companies we follow on the same exchange. Since 2026, the database holds 2 purchases and no sales by insiders of the company.
The latest purchase dates back some time: it was published 48 days ago, on 31 August 2026. Between a trade and the moment it shows up on SEDI, the median delay is 1 day. That lag is the time during which only the insider knows about the trade.
Source: insider filings from SEDI. Past trades are no guide to future returns.
Insider Decl.
17
Thresholds
n/a
Buy Volume
€5,235
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleRoger John Dumoulin-White1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,710 of 23,476 companies
31.1
score / 100
Value20
Quality42
FCF yld-5.7%
Earn yld-7.0%
EV/EBITDA·
ROE-93%
Gross mgn62%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CA$0.18
Analyst consensus
1 analystsCA$0.70Target CA$0.70(+300%)CA$0.70
Income statement
RevenueCA$816.5k
Gross profitCA$507.1k62% margin
EBITDA-CA$3.8M-467% margin
Net income-CA$4.1M-504.7% margin
Valuation
P/Book7.6x
Beta0.41
Balance sheet & cash
Market capCA$54.3M
Total debtCA$458.1k
Free Cash Flow-CA$3.3M
Debt / Equity2%
Profitability & ownership
ROE-93.4%
ROA-42.7%
% insiders8.4%
% institutions0.0%
Last declaration on 31 August 2026
Declarations17 total
3,360 shares@ CA$0.320.0020% mcap0.4% of flowWarrantsTSXSEDI:4770252
3,360 shares@ CA$0.240.3% of flowCommon SharesTSXSEDI:4770251
Canonical exit: 22 Nov 2016 (T+90)
42,000 shares@ CA$0.180.014% mcap2.6% of flowCommon SharesTSXSEDI:4769514
Canonical exit: 25 Nov 2026 (T+90)
14,000 shares@ CA$0.320.0082% mcap1.7% of flowWarrantsTSXSEDI:4768689
14,000 sharesCommon SharesTSXSEDI:4768688
31,250 shares@ CA$0.320.018% mcap3.4% of flowWarrantsTSXSEDI:4768687
31,250 shares@ CA$0.240.014% mcap2.6% of flowCommon SharesTSXSEDI:4768686
29,000 shares@ CA$0.320.017% mcap3.3% of flowWarrantsTSXSEDI:4768685
29,000 shares@ CA$0.240.013% mcap2.5% of flowCommon SharesTSXSEDI:4768684
3,360 shares@ CA$0.320.0020% mcap0.4% of flowWarrantsTSXSEDI:4768656
3,360 shares@ CA$0.240.0015% mcap0.3% of flowCommon SharesTSXSEDI:4768654
1,000,000 shares@ CA$0.2650.49% mcap100.0% of flowOptionsTSXSEDI:4764262
1,000,000 shares@ CA$0.2650.49% mcap99.6% of flowOptionsTSXSEDI:4762420
1,000,000 shares@ CA$0.2650.49% mcap94.2% of flowOptionsTSXSEDI:4761567
1,000,000 shares@ CA$0.2650.49% mcap98.3% of flowOptionsTSXSEDI:4761562
1,000,000 shares@ CA$0.2650.49% mcap91.4% of flowOptionsTSXSEDI:4761558
1,000,000 shares@ CA$0.2650.49% mcap99.3% of flowOptionsTSXSEDI:4761476
17 of 17 declarations
About Theralase Technologies Inc.
Theralase Technologies Inc. is a Canadian company focused on developing medical technologies, particularly laser treatment systems. It aims to eradicate cancer and manage pain.
